Asthma severity as a contributing factor to cancer incidence: A cohort study.

BACKGROUND: A putative link between asthma and asthma severity with the occurrence of cancer has been suggested but has not been fully investigated. The objective of this study is to assess the incidence of all types of cancer in a cohort of asthmatic patients. METHODS AND
FINDINGS: A single center cohort retrospective study was conducted to investigate the role of asthma as a potential risk factor for various cancers. Participants were followed for a period of 9 years from 01/01/2010 to 30/12/2018 and cancer incidence and its determinants were collected in asthmatic patients and controls from the same population source but without any respiratory disease. Overall, 2,027 asthma patients and 1,637 controls were followed up for an average of 9 years. The statistical analysis showed that 2% of asthma patients were diagnosed with various cancers, resulting in an incidence rate of cancer of 383.02 per 100,000 persons per year which is significantly higher than the 139.01 per 100,000 persons per year observed in matched controls (p-value < 0.001). The top four cancers reported among asthmatics were breast, colon, lung and prostate cancer. Lung cancer in asthmatics had the longest diagnosis period with a mean of 36.6 years compared to the shortest with prostate cancer with 16.5 years.
CONCLUSIONS: This study shows that asthma patients are at increased risk of different types of cancers with asthma severity and goiter as the main factors that may increase the risk of developing cancers among asthmatic patients.

Introduction

Worldwide incidence of cancer is on the rise. In 2018, 18.1 million new cases were reported with 9.6 million deaths. One in 5 males and one in 6 females worldwide develop cancer during their lifetime, and one in 8 males and one in 11 females die from the disease [1].

The increase of cancer incidence has prompted research on the factors that play a role in promoting or protecting against oncogenesis [2-4]. One of the main areas of interest has been the relationship between cancer and chronic inflammatory diseases. Recent evidence strengthened the concept of an association of inflammation and cancer [5-7] and nowadays it is generally accepted that up to 25% of human malignancies are related to chronic inflammation and to viral or bacterial infections [8]. One of the common conditions that affects the lung, where inflammation and the immune response are heavily implicated, is asthma. Global Initiative for Asthma (GINA) describes asthma as a heterogeneous disease, usually characterized by chronic airway inflammation with signs of wheezing, cough, dyspnea and chest tightness [9]. Asthma severity varies between the individuals and within the individuals overtime [9]. In mild-moderate asthma, using bronchodilators, inhaled corticosteroids (IC) and asthma management plan is the basis of effective treatment [10]. Moreover, there are 3–10% [10-12] of asthmatic patients who fail to respond to standard therapy and are categorized as severe asthmatics. Therefore, asthma severity is defined as “asthma which requires maximum controller therapy to prevent a patient from becoming uncontrolled or which, despite high dose therapy remains uncontrolled” [12]. Patients with severe asthma suffer from significant difficulties in daily living and decrease in physical activity and work productivity [12, 13]. Furthermore, they face increased comorbidity burden [12].

It is believed that allergies and asthma, inflammatory conditions commonly characterized by immunoglobulin E (IgE)-mediated atopic reactions [14], may either decrease cancer risk via increase in immunosurveillance or may increase risk due to persistent immune stimulation [15]. Recent studies demonstrated that the association between history of allergic disorders and asthma, and the risk of cancer varied by cancer types [16-19]. A protective effect of atopic diseases against pancreatic cancer [20, 21] has been shown consistently in case-control studies but not in cohort studies. Most studies on atopic diseases and non-Hodgkin lymphoma or colorectal cancer reported an inverse association. Inversion association between cancer and asthma have been reported in case-control studies of glioma [22, 23], and leukemia [24, 25]. In addition, controversial results have been reported in several studies in lung and breast cancer [15, 18, 19, 26–30]. However, the studies showing no association are based largely on qualitative data and rely on surveys. In addition, misdiagnosis of non-asthmatic conditions as uncontrolled asthma has been reported to be as high as 12–30% [12]. This might be because asthma symptoms may be similar to symptoms in other lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema and chronic bronchitis. Interestingly, similar symptoms to severe asthma can also be seen in patients with early symptoms of lung cancer [31]. Asthmatic patients and even their treating physicians may delay diagnosis for these symptoms and attribute them to uncontrolled asthma. In addition, non-smoker patients with asthma are generally excluded from high-risk group eligible for lung cancer screening [32]. Most patients delay seeking medical care until ominous symptoms like hemoptysis, pain, pleural effusion or distant metastasis develop, however by then radiological studies would most of the time detect late-stage lung cancer that is beyond surgical cure.

Therefore, using patient data records, rather than surveys, and stratifying asthma severity is highly needed to address these limitations and to more fully evaluate associations between asthma and specific cancer sites. The aim of this study is to investigate the role of asthma as a potential risk factor for cancer using clinical records of patients from the main referral hospital for respiratory disease in the UAE, and if present to identify the factors contributing to this association.

Materials and methods

Ethical consideration

All patient records were collected from the computerized information health system in Dubai Health Authority. All records in the outpatient and inpatient register, containing a hospital-discharge diagnosis of asthma. The data accessed were from 24/9/2019–30/4/2020. All patients were consented. Patient records were fully anonymized prior to access.

The study protocol was reviewed and approved by Dubai Scientific Research Ethical Committee (DSREC) Dubai Health Authority; the ethical approval number of the study is DSREC-SR-03L2019_01.

Study population

Asthmatic cases

The details of the study cohort were derived retrospectively from the medical records department in Rashid Hospital and Dubai Hospital which are part of the Dubai Healthcare Authority. UAE patients (local Emirati and expatriates) diagnosed with asthma follow-up at Rashid Hospital whereas patients with cancer follow-up in Dubai Hospital. Yearly, around 600–700 patients examined in Rashid Hospital are diagnosed with asthma as primary diagnosis (ICD-10 code). Each patient has a unique health card number, which is used to identify each case and ensure no duplication in the records. The records of patients diagnosed with asthma between January 1, 2010 and December 31, 2018 were retrieved. The total number of asthmatic patients identified was 2027 (prevalent cases). Patients were eligible for inclusion if they were 20 years old or older, were diagnosed with asthma as primary diagnosis (ICD-10 code) at time of discharge as in-patients or after their visit in the outpatient clinic and had more than one visit for at least one year in the hospital before 2010. Power calculation based on similar studies but a different population such as Boffetta P et al. (20), showed that a minimum of 1345 asthmatic patients is needed to identify sufficient cohort of cancers to determine whether an association between asthma and cancer exist. The parameters for the power calculation were chosen as follows: significance level = 0.05, power = 90%, the standard deviation = 16 and effect size = 2 were obtained from Boffetta P et al. which carried out the study on Swedish population. Therefore, the final total number of 1886 identified from the records (Fig 1) is sufficient for the study. For the classification of asthma severity, we followed GINA guidelines [9] (S1 Table) where mild asthma is described as patients prescribed step 1–2 treatment, whereas moderate asthma is defined as patients prescribed treatment step 3–4 without history of asthma exacerbation or one in the last year of participation of the study. Severe asthma is defined as patients prescribed treatment step 4–5 with history of at least 2 exacerbations in the last year and/or a history of hospital admission for acute severe asthma in the last year of participation in the study.

Fig 1

The flow chart of the study methodology.

In order to identify cancer patients (incidence cases) within the asthma cohort, all cohort linked to cancer registry in Dubai Health Authority were classified according to the ICD-10 code. The clinical records were retrieved, and cancer diagnosis was reviewed. The analysis was restricted to include cases diagnosed with cancer during the study period and excluded eighteen cases diagnosed with cancer before January 1, 2010. The total cohort, which includes all patients who followed up from beginning of 2010 until end of 2018, was 1868 patients with 38 patients diagnosed with different types of cancer.

Control cases

Matched controls against age and gender with persons attending the same hospitals but with other diseases were used (n = 2262). The inclusion criteria for controls were 20 years old or older, no past or present diagnosis of asthma and other pulmonary diseases and other symptoms of allergic diseases such as nasal and skin symptoms. Control patients were free of malignancy at the time of recruitment between January 1, 2010 and December 31, 2018. A total of 600 patients were excluded according to the criteria and 1662 patients were identified. In order to identify cancer patients within the control, all records linked to cancer registry in Dubai Health Authority were classified according to the ICD-10 code. The clinical records were retrieved, and cancer diagnosis was reviewed. The analysis was restricted to include cases diagnosed with cancer during the study period and excluded 25 cases diagnosed with cancer before January 1, 2010. The total control cases were 1637 (Fig 1).

Statistical analysis

Parametric tests including descriptive analysis, incidence analysis was used for quantitative variables. Fisher exact test, the Chi-squared test and Cox logistic regression were applied for association analysis and comparison of categorical variables. Kaplan-Meier survival analysis was carried out to determine the progression of patients from asthma to cancer and log rank was used to determine whether the variables compared are significant. Two-sided p values <0.05 were considered to be statistically significant. Statistical package SPSS (version 24) was used for statistical analyses.

Univariate analysis

In order to identify the individual risk variables, univariate analysis on each independent variable was applied to the asthmatic cohort. The independent variables consisted of demographic variables, including age, sex, nationality, smoking status, asthma severity as well as comorbid conditions, including, cardiovascular diseases, type 2 diabetes mellitus (T2DM), hypertension (HTN), obstructive sleep apnea (OSA), allergic rhinitis (AR), gastroesophageal reflux disease (GERD), urticaria, hyperlipidemia, obesity, hypothyroidism, goiter and auto-immune diseases including, irritable bowel disease (IBD), rheumatoid arthritis and Hashimoto’s thyroiditis. All selected variables were tested for co-linearity to avoid any strong correlation between the variables. The presence of co-linearity was examined by the evaluation of variance inflation factors and magnitude of standard errors. Variables with more than 30% missing values were not included in the analysis.

Multivariate analysis

The variables that were significant from the univariate analysis were incorporated into multivariate Cox regression model. The multivariate Cox regression was used to determine the degree of interaction between the different variables obtained from the patients’ records. The aim of this is to identify which set of variables are key in driving the association between cancer and asthma and their degree of interaction.

In addition, progression from asthma to lung cancer was studied by organizing the data in chronological order of patients who developed asthma and later on progressed to lung cancer. The data was organized according to age at diagnosis of asthma, age at diagnosis of lung cancer, stage of the lung cancer at diagnosis, duration between the diagnosis of asthma and lung cancer and number of asthma attacks per year over the period of their follow up.

Results

Descriptive statistics using patient cohort identified in this study are shown in Table 1.

Table 1

Characteristics and comorbidities for asthmatic and control patients during 2010–2018.

Basic Demographic	Asthmatic cases n = (1868)	Controls n = (1637)	P value
Gender (F) N (%)	1264(68)	1128(69)	0.226
Age (in years) M ± SD	50 ±16.4	52 ± 13.8	0.294
Nationality (Emirati) N (%)	1627(87)	1408(86)	0.186
Smoking History (Smoker) N (%)	241(13)	225 (14)	0.247
Developed cancer N (%)	38(2)	20 (1.2)	0.039

Table 1 shows that the total asthmatic patients in the cohort were 1868 patients with a mean age of the cohort study of 50 ±16.4 years compared to 52 ±13.8 years for control patients. Females comprised 68% of the asthmatic cohort and Emirati nationals were 87% compared to 69% and 86% respectively in the control patients. 13% of asthmatic patients had a history of smoking compared to 14% in control patients. Table 2 shows the top four cancers in asthmatic patients compared to control group. Detailed analysis of the asthmatic cohort of all comorbidities reported including the asthma severity (S2 Table) shows that the affected individuals with the selected co-morbidities are much less than the unaffected individuals, resulting in a difficulty in identifying epidemiological patterns in the data. However, the small number of affected individuals does show that there is a link between autoimmune, allergic disease, thyroid and asthma.

Table 2

Number and incidence of cancer per 1 million person-months among asthmatic cohort compared to controls.

Asthmatic Cases who developed Cancer N (%)		Asthmatic (Incidence of cancer per 1 million per person-months)	Control Cases who developed Cancer N (%)		Controls (Incidence of cancer per 1 million per person- months)
Breast Cancer	11 (0.6)	93.75	Breast Cancer	5 (0.3)	30.8
Colon Cancer	8 (0.4)	68.18	Brain Tumor	2 (0.1)	12.32
Lung Cancer	6 (0.3)	51.13	Papillary Thyroid Cancer	2 (0.1)	12.32
Prostate Cancer	2 (0.1)	17.04	Prostate Cancer	2 (0.1)	12.32

In terms of cancers, we identified that out of 1868 cases of asthma followed for 9 years, 38 (2%) patients were diagnosed with cancer compared to 20 (1.2%) control patients; this makes the incidence rate of cancer among asthmatics 383.02 per 100,000 person per year compared to 139.01 per 100,000 person per year. There is a significantly higher incidence among asthma patients compared to control patients (p-value < 0.001).

The incidence rate presented in Table 3 shows that the leading cancers among the asthmatic cohort are: breast cancer (n = 11) with 93.8 per 1 million person-months; colon cancer (n = 8) with 68.2 per 1 million person per month; lung cancer (n = 6) with 51.1 per 1 million person per month and prostate cancer with 17 per 1 million persons per months. Whereas the control cohort showed the following top four cancers: breast cancer (n = 5) with 30.8 per 1 million person per months; brain tumor (n = 2) with 12.32 per 1 million person per months; papillary thyroid cancer (n = 2) with 12.32 per 1 million person per months; prostate cancer (n = 2) with 12.32 per 1 million person per months. The data show that the top two cancers (breast and colon) are driven by hormonal status followed by lung cancer. Therefore, lung cancer is the top disease outside the hormonal-driven cancers.

Table 3

Association between cancer among asthma patients and other co-morbidities.

Comorbidities	Asthmatic patient free from cancer n(%)	Asthmatic patient with cancer n(%)	OR (95%CI)	p-value
Goiter	16(1)	4(11)	13.34(4.24–41.91)	0.001
HTN	412(23)	17(45)	2.79(1.146–5.33)	0.002
Hyperlipidemia	269(15)	11(29)	2.36(1.16–4.82)	0.019
Cardiovascular	96(5)	5(13)	2.74(1.05–7.17)	0.051
AR	677(37)	10(26)	0.61(0.30–1.26)	0.117
DM	455(25)	13(34)	1.57(0.80–3.10)	0.13
IBD	6(0.3)	1(3)	8.22(0.97–69.96)	0.134
Autoimmune Disease	91(5)	3(8)	1.64(0.49–5.43)	0.298
Hashimoto’s Thyroiditis	17(1)	1(3)	2.88(0.37–22.23)	0.31
Urticaria	19(1)	1(3)	2.58(0.34–19.75)	0.338
OSA	119(7)	3(8)	1.23(0.37–4.07)	0.457
GERD	87(5)	2(5)	1.11(0.26–4.70)	0.549
Hypothyroidism	95(5)	2(5)	1.02(0.24–4.28)	0.596
Rheumatoid Arthritis	62(3)	1(3)	0.77(0.10–571)	0.631

Univariate analysis of asthma variables

The univariate analysis between asthma patients with cancer and asthma patients without cancer (S3 Table) in relation to the demographic data (gender, nationality, history of smoking) and the severity of asthma was assessed and Q-Q plot was used to check the normality distribution. The results show that there was no indication of increased risk of cancer in relation to the following variables: smoking (p = 0.21), gender (p = 0.462) and nationality (p = 0.21). However, severity of asthma in patients with cancer was statistically significant (p<0.001) with significant differences between mild asthmatic compared to moderate and severe asthma (p<0.001) while there were no significant changes between moderate and severe asthma (p<0.082). Interestingly, 82% of asthmatic patients who didn’t smoke developed cancer.

Table 3 shows the univariate analysis between asthma patients with cancer and asthma patients without cancer in relation to other co-morbidities. Results show that patients with HTN had 2.79 (95%CI; 1.146–5.33) times more chance of developing cancer compared to patients without HTN. Similarly, patients with hyperlipidemia had 2.36 (95%CI; 1.16–4.82) times more chance of developing cancer compared to patients without hyperlipidemia. Interestingly patients with goiter had 13.34 (95%CI; 4.24–41.90) times more chance of developing cancer compared to patients without goiter.

Multivariate analysis using Cox-Model

Table 4 shows multivariate analysis using Cox-Model. In this model, we use the variables of cancer (dichotomous variables) as dependent variables and all the variables that are significant using univariate analysis (age, asthma severity, HTN, hyperlipidemia and goiter).

Table 4

Multivariate analysis using Cox-Model of the significant variables identified from the univariate analysis of the asthmatic cohort with and without cancer.

Variables	B	Sig.	Exp(B)	95.0% CI for Exp(B)
				Lower	Upper
Age Group	1.133	0.015	3.104	1.241	7.763
Asthma Severity	1.074	0.000	2.929	1.784	4.807
HTN	0.242	0.491	1.273	0.641	2.531
Hyperlipidemia	-0.072	0.848	0.930	0.444	1.948
Goiter	2.280	0.000	9.781	3.260	29.348

A multivariate Cox proportional hazards regression analysis adjusted for age, asthma severity, hypertension, hyperlipidemia and goiter revealed that among the cohort asthma severity (p< 001; 95% CI, 2.005–5.389) and goiter (p = 0.10; 95% CI, 0.018–0.576) were a risk for developing cancer. The data show that severity and goiter remain significant in the Cox model analysis suggesting that there might be a link between goiter and asthmatic disease.

Effect of asthma persistence/progression on the onset of cancer

Fig 2 shows the effect of asthma persistence or progression on the onset of cancer. The data shows that there are significant differences (p < 0.001) between (mild- moderate) asthmatic and (mild-severe) asthmatic progression towards developing cancer while between (moderate-severe) asthmatic was marginal (p = 0.04).

Fig 2

Speed of the occurrence of cancer among asthma patients associated with severity of asthma.

Fig 3 describes the average number of years for cancer diagnosis according to the top four cancers identified in Table 2. Lung cancer diagnosis was revealed to have the longest diagnosis period with an average of 36.6 years compared to prostate cancer with 16.5 years. This indicates that asthma might play a role in developing cancer through low level perturbation of the tissue.

Fig 3

Average of years between asthma and cancer diagnosis.

50% of lung cancer with asthma patients are diagnosed with stage 4 lung cancer (S1 Fig). This is typical in lung cancer as most of the cases in lung cancer tend be in the later stages of the disease. Interestingly, a similar number is found for prostate cancer where 50% of patients have early prostate cancer patients compared to 50% with aggressive prostate cancer. This suggests that inflammation and chronic inflammation play a role in eventually establishing cancer since prostate cancer is an indolent disease characterized by long term chronic inflammation which eventually develops into cancer after a lengthy period. On the other hand, colorectal and breast cancers are more aggressive and perhaps asthma indirectly contribute to its progression. Comparison between alive and dead asthmatic cases from the top four type of cancer in asthmatic cohort (S2 Fig) was assessed. Data shows that prostate cancer has the highest survival because it is indolent whereas lung cancer has the lowest survival because it is generally diagnosed at late stage.

Later stages of cancer show poor survival of around 57 months whereas stages 2 to 3 show longer survival of asthmatic patients whereas in control patients the survival is 80 months (Fig 4). This indicates that asthma contributes to poorer survival of cancer patients. The outcome from this is supported by the finding in S2 Fig.

Fig 4

Kaplan-Meier survival curve among asthmatic and control patients.

(A) Kaplan-Meier survival curve showing the speed of the occurrence of death amongst asthma patients who had cancer at different stages. There was no significance in death progression among patients who in stage 1,2, and 3 (P = 0.2) but there were significant between stage 1,2 and 4 (P = 0.01). (B) Kaplan-Meier survival curve showing the speed of the occurrence of death amongst control patients with cancer at different stages.

Since we have shown that the average years for lung cancer diagnosis among the asthma cohort was high, we were interested to further examine this cohort of patients. Fig 5 shows the details of the follow-up of the 6 cases of lung cancer with asthma patients. Cases 1 and 4 show patients were diagnosed with asthma at the ages of 46 and 41 years respectively. These patients were then diagnosed with stage 4 lung cancer at ages 80 and 79 years respectively. Interestingly, these patients had recurrent admissions to the hospital and were on long-term use of inhaled steroid therapy for asthma. Fig 4 shows that moderate asthma lead to stage II lung cancer but severe asthma lead to the more aggressive stage 3 and 4 lung cancer. This is important as it indicates that asthma plays a contributing factor to lung cancer and may be used as an early predictor of the disease. Fig 5 shows that once cancer has been established, the follow-up after cancer diagnosis is variable and probably depends on the severity of asthma.

Fig 5

Follow-up for asthmatic cases who developed lung cancer.

Discussion

To date, asthma and lung cancer are viewed as independent diseases although they affect the same organ and share common clinical manifestations. In this study, we have shown that asthma may, in some cases, be a precursor to lung cancer where asthma is an inflammatory disease. Infections or injuries result in the disruption of tissue homeostasis, triggering an inflammatory response initiated by the innate immune system followed by a coordinated response by the adaptive immune system. Various mechanisms can be used by the innate immune cells to initiate inflammation including the release of cytokines, chemokines, matrix-remodeling proteases, and reactive species. However, imprecise regulation of these mechanisms of inflammation can adversely result in chronic inflammation and pro-tumor microenvironment [33]. The mechanisms used by inflammatory conditions to promote tumor growth are numerous, extremely complex and involve lengthy processes. Asthma is a heterogeneous disorder of the conducting airways involving chronic airway inflammation, declining airway function and tissue remodeling [34]. Asthma is thought to arise from the complex interplay of genetic susceptibility and environmental influences, such as timing and dose of allergen and co-exposure to infection [35].

To our knowledge this is the first study in the Middle East examining the association between asthma and risk of cancer, which is important because of the different lifestyles of the analyzed patients, which influences the prevalence of asthma and cancers. In this study, association was observed between history of asthma and risk of various cancers. In our study, asthma was associated mainly with increased risk of breast, colon, lung, and prostate cancers which is consistent with data from other publications [17, 19, 26–28, 36, 37]. This is of interest because the hypothesized mechanisms by which allergies and asthma are suspected to affect cancer risk is expected to apply regardless of site [15].

We confirmed through the univariate analysis, that gender and smoking habits do not associate with the risk of cancer. Interestingly, asthma severity shows that there is an association between cancer and asthma. These results suggested that asthma might be an independent risk factor for cancer.

A noteworthy finding in our study was that severe asthmatic patients with goiter were significantly associated with higher speed of the occurrence of cancer cases compared to mild and moderate asthmatic patients. Goiter is an abnormal enlargement of thyroid gland. The location of the gland makes this enlargement important because it can compress the trachea [38]. The relationship between asthma and thyroid problems has been documented in many studies [39-44] and correction of hypothyroidism causes worsening of symptoms and difficulties in controlling asthma [44]. Goiter is due to an imbalance in the regulation of thyroid hormones brought on by iodine deficiency, rare inherited disorders of the thyroid gland or autoimmune diseases such as Hashimoto thyroiditis and Grave’s disease. The loss of immunological tolerance to thyroid antigens leads to the generation of components of the cellular and humoral arms of the adaptive immune response. The infiltration of lymphocytes (more specifically T lymphocytes) and/or the generation of pathogenic autoantibodies causes damage to the thyroid and modifies the response of the thyroid gland [45]. There is reduced responses to bronchodilator therapy with an inverse relationship between levels of thyroid function and airway beta adrenergic responsiveness [41]. Taken together, this may explain the increase in severity of asthma among this group due to goiter.

In our study, this was established through careful assessment of asthmatic cases by doing full review for their past medical history with different comorbidities and level of asthma severity and this is the first study in the region. In addition, the follow-up analysis of the patients identified a subset of 6 patients (2%) that were diagnosed with both asthma and lung cancer and the survival analysis showed that asthma can be a contributing factor to cancer progression and especially lung cancer. This provides solid evidence of the association between asthma and lung cancer and 2% is in line with the data published by Boffetta et al [26]. The main limitation of our study is that it is from one center, but it is the largest center in the UAE.

Thus, the most prominent finding in our study is the positive association between asthma severity and progression of developing different cancer types. Ji and colleagues showed in their study that the asthmatic patients with multiple hospital admissions had a high risk of developing different types of cancer, particularly for stomach (SIR 1.70) and colon cancers (SIR 1.99) [36].

In summary, our results show real association between asthma and lung cancer by identifying a subset of patients that were diagnosed with both diseases. In addition, our study showed through epidemiological analysis that asthma can be a contributing factor to carcinogenesis and its progression in various tissues and specifically the lung, warranting further studies to understand the molecular basis of the link between asthma and lung cancer.

GINA guidelines step-up medications.

(TIF)

Click here for additional data file.

Detailed comorbidities for asthmatic patients during 2010–2018 period.

(TIF)

Click here for additional data file.

Association between cancer, demographic data and asthma severity among the cohort.

(TIF)

Click here for additional data file.

Percentage of cancer stages for the top four cancers in the cohort.

(TIF)

Click here for additional data file.

Percentage of death among the top four cancers in asthma cohort.

(TIF)

Click here for additional data file.

(SAV)

Click here for additional data file.

(SAV)

Click here for additional data file.

16 Mar 2021

PONE-D-20-38174

Asthma Severity as a Contributing factor to Cancer Incidence: A Cohort Study

PLOS ONE

Dear Dr. Al Heialy,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 30 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Maria Maddalena Sirufo

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

3. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records/samples used in your retrospective study, including the date range (month and year) during which patients' medical records/samples were accessed.

If patients provided informed written consent to have data from their medical records used in research, please include this information.

4. Please include a copy of Table 6 which you refer to in your text on page 11.

5. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 4 in your text; if accepted, production will need this reference to link the reader to the Table.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This retrospective single-center cohort study evaluates the incidence of all cancer types in a population of asthma patients compared to a control population followed over a 9-year time interval. The role of asthma as a potential cancer risk factor is then evaluated.

This cohort study is well constructed. I would suggest a re-reading of the work in order to carry out a grammatical revision; for example on line 234: "the shows that ..."

The introduction investigates the relationship between cancer and chronic inflammatory diseases focusing on asthma. In the introduction we find: "Recent studies demonstrated that the association between history of allergic disorders and asthma, and the risk of cancer varied by cancer types". I would ask the authors to develop this part of the introduction more.

Reviewer #2: This paper is very well written. The results are very interesting for readers.The authors' conclusions are consistent with the data reported in the paper. I n conclusion the paper deserves to be published.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Urso Domenico Lorenzo

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

31 Mar 2021

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

3. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records/samples used in your retrospective study, including the date range (month and year) during which patients' medical records/samples were accessed.

If patients provided informed written consent to have data from their medical records used in research, please include this information.

We thank the editor for pointing this out. We have added the following paragraph in lines 85-89.

“All patient records were collected from the computerized information health system in Dubai Health Authority. All records in the outpatient and inpatient register, containing a hospital-discharge diagnosis of asthma. The data accessed were from 24/9/2019 – 30/4/2020. All patients were consented. Patient records were fully anonymized prior to access.”

4. Please include a copy of Table 6 which you refer to in your text on page 11.

We thank the editor for pointing out the anomaly. In fact, there is no Table 6. Table 4 was mislabeled as Table 6. This correction has been made in line 224.

5. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 4 in your text; if accepted, production will need this reference to link the reader to the Table.

Thank you for pointing out the anomaly. In fact, there is no Table 6. Table 4 was mislabeled at Table 6. This correction has been made in line 224.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This retrospective single-center cohort study evaluates the incidence of all cancer types in a population of asthma patients compared to a control population followed over a 9-year time interval. The role of asthma as a potential cancer risk factor is then evaluated.

This cohort study is well constructed. I would suggest a re-reading of the work in order to carry out a grammatical revision; for example on line 234: "the shows that ..."

We thank the reviewer for taking the time to read through the manuscript. We have carefully gone through the manuscript and corrected the grammatical and other linguistic errors identified.

The introduction investigates the relationship between cancer and chronic inflammatory diseases focusing on asthma. In the introduction we find: "Recent studies demonstrated that the association between history of allergic disorders and asthma, and the risk of cancer varied by cancer types". I would ask the authors to develop this part of the introduction more.

We thank the reviewer for raising this point and agree that it is important to expand on it to introduce the fact that the relationship between the association of asthma and cancer. We have added the following statement in line 61-64:

“A protective effect of atopic diseases against pancreatic cancer has been shown consistently in case-control studies but not in cohort studies. Most studies on atopic diseases and non-Hodgkin lymphoma or colorectal cancer reported an inverse association.”

Moreover, this completes the statement in line 64-65:

“Inversion association between cancer and asthma have been reported in case-control studies of glioma [22, 23], and leukemia [24, 25].”

Reviewer #2: This paper is very well written. The results are very interesting for readers.The authors' conclusions are consistent with the data reported in the paper. I n conclusion the paper deserves to be published.

We thank the reviewer for their complimentary comments and for giving their time to go through the manuscript. We hope that the manuscript can add to the existing body of knowledge on the association between asthma and lung cancer.

________________________________________

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Urso Domenico Lorenzo

Submitted filename: Response to reviewers Final.docx

Click here for additional data file.

7 Apr 2021

Asthma Severity as a Contributing factor to Cancer Incidence: A Cohort Study

PONE-D-20-38174R1

Dear Dr. Al Heialy,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Maria Maddalena Sirufo

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

16 Apr 2021

PONE-D-20-38174R1

Asthma Severity as a Contributing factor to Cancer Incidence: A Cohort Study

Dear Dr. Al Heialy:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Maria Maddalena Sirufo

Academic Editor

PLOS ONE